{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:18:07Z","timestamp":1778987887276,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Complementary and alternative medicine (CAM) encompasses a wide range of medication, herbal, dietary and physical therapies that are not usually considered within the realm of conventional therapeutics. Approximately two thirds of the Australian population use CAMs and only around half of this number will discuss their use of these products with their doctor. Clinical use is commonly seen in patients with life\u2010limiting illness, often because they experience a high burden of symptoms. However, it is also the case that many of these therapies do not have demonstrated efficacy, particularly for the often broad list of conditions and symptoms for which they are chosen to be used. Further, depending on whether they are sold as medications, sold as food supplements or imported illegally and distributed via nonstandard therapeutic channels, several products have had reports of toxicity, severe adverse effects, batch irregularities and drug interactions with other therapies. This awareness, together with lack of standardisation of products and lack of interchangeability between brands has made prescribers unwilling to put patients at risk of harm by supporting their use. In this article, we cover general pharmacological principles around use of a small selection of chemicals used in a medical setting to enable some guidance for use.<\/jats:p>","DOI":"10.1111\/imj.15922","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T01:09:40Z","timestamp":1666314580000},"page":"1677-1684","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Complementary and alternative therapies in the palliative setting"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-0199","authenticated-orcid":false,"given":"Jennifer H.","family":"Martin","sequence":"first","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Division of Medicine John Hunter Hospital  Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Patel","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Department of Palliative Care Calvary Mater Newcastle  Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Australian Government National Health and Medical Research Council. Talking with your patients about Complementary Medicine \u2013 a Resource for Clinicians. NHMRC; April 2014. Available from URL:https:\/\/www.nhmrc.gov.au\/about-us\/publications\/talking-your-patients-about-complementary-medicine-resource-clinicians#block-views-block-file-attachments-content-block-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2018.07.016"},{"key":"e_1_2_9_4_1","unstructured":"Therapeutic Goods Administration. Listed Medicines. Available from URL:http:\/\/www.tga.gov.au\/listed-medicines"},{"key":"e_1_2_9_5_1","unstructured":"Therapeutic Goods Administration. TGA reminds Australians of the potential danger of Pan Pharmaceuticals. Available from URL:https:\/\/www.tga.gov.au\/media-release\/tga-reminds-australians-potential-danger-pan-pharmaceuticals"},{"key":"e_1_2_9_6_1","volume-title":"Position Statement: The Use of Complementary and Alternative Medicines by Cancer Patients","author":"Clinical Oncology Society of Australia","year":"2013"},{"key":"e_1_2_9_7_1","unstructured":"Therapeutic Guidelines Pain and Analgesia. Adjuvants in Pain Management. Available from URL:https:\/\/tgldcdp.tg.org.au.acs.hcn.com.au\/viewTopic?topicfile=adjuvants-pain-management#toc_d1e227"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092447"},{"key":"e_1_2_9_9_1","unstructured":"Therapeutic Drugs Administration. Medicinal Cannabis: Role of the TGA. Available from URL:https:\/\/www.tga.gov.au\/medicinal-cannabis-role-tga"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15262"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14028"},{"key":"e_1_2_9_12_1","unstructured":"Therapeutic Goods Administration. Epidyolex. Available from URL:https:\/\/www.tga.gov.au\/apm-summary\/epidyolex"},{"key":"e_1_2_9_13_1","unstructured":"Therapeutic Goods Administration. Sativex nabiximols. Available from URL:https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-nabiximols-130927-pi.pdf"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/18-041"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4090"},{"key":"e_1_2_9_16_1","unstructured":"Australian Clinical Trials. Cannabinoids for Symptom Control in Advanced Cancer An Open Label Prospective Clinical Trial in New South Wales. Available from URL:https:\/\/www.australianclinicaltrials.gov.au\/anzctr\/trial\/ACTRN12619000265178"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.07.031"},{"key":"e_1_2_9_18_1","unstructured":"Therapeutic Guidelines Psychotropic. Insomnia in Adults. Available from URL:https:\/\/tgldcdp.tg.org.au.acs.hcn.com.au\/viewTopic?topicfile=insomnia-adults&sectionId=ptg8-c40-s5#ptg8-c40-s5-3"},{"key":"e_1_2_9_19_1","unstructured":"Centre for Palliative Care. Melatonin Study. Available from URL:https:\/\/www.centreforpallcare.org\/news\/15\/the-31st-nurse-practitioner-joint-forum"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13695"},{"key":"e_1_2_9_21_1","first-page":"228\u201337","article-title":"Expert advice for prescribing cannabis medicines for patients with epilepsy\u2010drawn from the Australian clinical experience","volume":"52","author":"Lawson J","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_9_22_1","unstructured":"MIMS Online. Circadin Product Information. Available from URL:https:\/\/www.mimsonline.com.au.acs.hcn.com.au\/Search\/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=circadin&PreviousPage=~\/Search\/QuickSearch.aspx&SearchType=&ID=85440001_2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13710"},{"key":"e_1_2_9_24_1","unstructured":"Up to Date. Complementary and Alternative Therapies for Cancer. Available from URL:https:\/\/www.uptodate.com.acs.hcn.com.au\/contents\/complementary-and-alternative-therapies-for-cancer?search=diet%20and%20cancer&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H15"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.JOMFP_126_19"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.011"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05373-8"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.509714"},{"key":"e_1_2_9_29_1","unstructured":"Memorial Sloan Kettering Cancer Center. About Herbs Botanicals and Other Products. Available from URL:https:\/\/www.mskcc.org\/cancer-care\/diagnosis-treatment\/symptom-management\/integrative-medicine\/herbs"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2409-9"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079603"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00399.x"},{"key":"e_1_2_9_33_1","unstructured":"National Centre for Complementary and Integrative Health. Americans Spend $30 billion a Year Out\u2010Of\u2010Pocket On Complementary Health Approaches. Available from URL:https:\/\/www.nccih.nih.gov\/research\/research-results\/americans-spend-30-billion-a-year-outofpocket-on-complementary-health-approaches"},{"key":"e_1_2_9_34_1","first-page":"CD007076","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry S","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_35_1","first-page":"CD012182","article-title":"Cannabis\u2010based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke M","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15635"},{"key":"e_1_2_9_37_1","volume-title":"Understanding Complementary Therapies","author":"Cancer Council Australia","year":"2018"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","unstructured":"H\u00e4gg S J\u00f6nsson AK Ahlner J. Current Evidence on Abuse and Misuse of Gabapentinoids.Drug Saf2020;43: 1235\u201354.https:\/\/doi.org\/10.1007\/s40264-020-00985-6","DOI":"10.1007\/s40264-020-00985-6"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.15922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:39:11Z","timestamp":1692671951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.15922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/imj.15922"],"URL":"https:\/\/doi.org\/10.1111\/imj.15922","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}